DIVINCELL SAS is a BioPharmaceutical NanoMedicine company, specializing in the preclinical and pharmaceutical development of innovative solutions for targeted drug delivery in the treatment of cancers and genetic diseases.
Founded in 2018, DIVINCELL has established an unique intellectual property expertise and know-how based on 25 years of research in the field of nanomedicine and drug delivery.
DIVINCELL has developed a Nanocages platform DIV’INTM , based on amphipathic peptides, able to target active drug inside pathologic cells without affecting the physiology of healthy cells.
Our versatile breakthrough technology offers innovative solutions to tackle the limitation of targeting and cellular-releasing of therapeutic agents (nucleic acid, protein, peptide …) and provides an effective drug delivery system for a wide range of clinical applications and pathologies (cancer, metabolic disorders, fibrosis, etc.).
The DIV’INTM platform has been validated by numerous studies using therapeutic cancer models (osteosarcoma, pancreas, colorectal and lung cancers…) and other therapeutic models (metabolic disorders, fibrosis….).
